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Keratoconus (KC) and iatrogenic keratoectasia are receiving
increasing attention, due to the improvements in diagnostic
modalities and the availability of therapeutic options, which
now include collagen cross-linking, intrastromal implants,
intraocular lenses, microwave remodeling, and anterior
lamellar keratoplasty.
Limitations of surgical treatments of keratoconus are
well known. Intrastromal implants, built in various shapes
and now implanted more safely through femtosecond-laser-
obtained stromal channels, still retain reduced predictability
as for the refractive results and do not modify the structure
of the diseased cornea. Anterior lamellar keratoplasty, even
in its more advanced and technically diﬃcult variant of deep
anterior lamellar keratoplasty (DALK), cures the disease by
the (almost) complete replacement of the ectatic stroma but,
even when a regular and transparent interface is achieved,
ﬁnal refractive errors and higher-order aberrations may
severely aﬀect visual rehabilitation. The use of femtosecond
laser in DALK to shape the donor and recipient margins has
not signiﬁcantly improved the picture yet.
Parasurgical treatments of KC are therefore regarded as a
temporary or deﬁnitive alternative to surgical interventions.
Among the newest ideas, the promising use of microwave
to heat and reshape the corneal apex shares the principle
with previous modalities of thermal keratoplasty, which
were characterized by regression and induction of irregular
astigmatism. The long-term validity of microwave reshaping
is, therefore, still being investigated.
The use of collagen corneal cross-linking (CXL) with
riboﬂavin and ultraviolet (UV) has rapidly expanded in
the world and is currently regarded as the only recognized
treatment to slow or arrest KC progression, obtaining in
some cases a signiﬁcant improvement of corneal curvature
and regularity. However, as most new treatments, CXL is
still far from being ideal. Riboﬂavin for CXL is unreason-
ably expensive; the treatment is long and tedious and is
followedbypostoperativepainandslowvisualrehabilitation.
Complications are not uncommon, including infections and
scarring. The indications to the treatment are still debated
as for age, KC stage, and corneal thickness. Alternative
attempts to reduce the CXL operating time by increasing
the irradiation energy or by avoiding epithelial removal have
been made, but all deviations from the deﬁned original
protocol may reduce the eﬃcacy of treatment, and therefore
new treatment protocols are currently further investigated.
In this special issue, various and new aspects of CXL
are examined, rehabilitation with contact lenses of KC is
reviewed, and the features of posterior KC at ultrasound
biomicroscopy are evaluated.
Patient selection for CXL is not completely codiﬁed, and
age limits are conventionally established. For example, the
Italian National Health Service limits CXL reimbursement2 Journal of Ophthalmology
for patients between 12 and 40 years, the lower limit being
dictated by common sense and the upper limit by the
presumption of spontaneous KC stabilization after 40. A.
Caporossi and Mazzotta et al., leading experts of CXL,
in their original study in this issue, compare KC stabi-
lization, improvement of corneal curvature, visual acuity,
and aberrations 48 months after CXL in diﬀerent age
groups, concluding that the highest beneﬁts were obtained
in younger eyes.
CXL procedure was originally developed to stiﬀen the
keratoconic cornea, but its indications have been recently
extended to postrefractive surgery ectasia, to infectious
keratitis (due to a powerful antimicrobial action), and to
corneal edema, where CXL temporarily reduces the space
for ﬂuid accumulation. These new indications of CXL, as
well as its physical and chemical background, biomechanical
eﬀects, and clinical results, are thoroughly reviewed in the
paper by M. Hovakimyan et al., where the real possibilities
of transepithelial CXL and of the new approach combining
photorefractive keratectomy (PRK) and CXL are discussed.
Several reports of infectious keratitis after CXL have
recently raised the issue of CXL safety: it would appear that
the risk of infection is considerably higher than after PRK.
The length of the procedure or the slow epithelialization
time could be the reasons for such increased infectious risk.
In addition, the peculiar “demarcation” haze, regarded as
a demonstration of the cross-linking eﬀect, can sometimes
turn into a signiﬁcant, long-term scar. These complications
and others are well reviewed in the paper by S. Dhawan et al.
Fortunately, most patients with KC will never need
to undergo any surgical or parasurgical procedure. Visual
rehabilitation is sometimes possible with the sole help of
spectacles, but the reduction of higher-order aberrations is
only possible with contact lenses. The extended wear of
contactlensesandthediﬃcultadaptationinkeratoconiceyes
imply a thorough knowledge of various contact lens models
available: this is the subject of the article by Ozkurt et al.
The paper by B. Rejdak et al. is a case report of a
rare, nonprogressive variant of KC, circumscribed posterior
keratoconus. The correct diagnosis of this form of ectasia
is only possible by modern three-dimensional imaging
technique,andinthiscaseultrasoundbiomicroscopyandslit
scanning topography were used to reveal the protrusion of
the posterior corneal surface.
In this historical period we are directly witnessing the
rise (and fall) of many therapeutic modalities for KC, but we
can nevertheless look with optimism at the future of a com-
plex and multiform disease, characterized by individualised
treatment and prognosis. We hope that this special issue will
contribute to stimulating discussion.
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